Method for preparing low-density lipoprotein affinity adsorption hemodialysis membrane material

Abstract

The invention belongs to the fields of membrane surface engineering and bioseparation engineering and aims at providing a method for preparing a low-density lipoprotein affinity adsorption hemodialysis membrane material. The method provided by the invention comprises the following steps: prewashing the hemodialysis membrane material; placing the prewashed hemodialysis membrane material into a plasma processor cavity; introducing inert gas and activated gas until atmosphere ingredients are constant and then carrying out plasma processing; immersing into a heparin solution; adding a coupling agent to carry out an oscillation reaction; carrying out oscillation washing by utilizing a PBS (Phosphate Buffer Solution); and repeatedly washing with clean water and perform filter drying to obtain the low-density lipoprotein affinity adsorption hemodialysis membrane material. In the method provided by the invention, active reaction groups are introduced into by utilizing a constant-pressure and low-temperature plasma activation modification processing method; the reaction is only carried out on the surface of the material, the body performance of the material is not influenced, and simultaneously the method has the characteristics of high efficiency, low cost, low energy consumption, environmental friendliness and the like; the hydrophilia and blood compatibility of the surface of a macromolecule separation membrane material can be greatly improved; and the blockage effect caused by membrane pollution in the hemodialysis course can be effectively reduced.

Description

technical field [0001] The invention belongs to the fields of membrane surface engineering and bioseparation engineering, and in particular relates to a preparation method of a modified separation membrane material used to realize synchronous and efficient adsorption and purification of low-density lipoprotein in the process of hemodialysis. Background technique [0002] According to an announcement jointly issued by the International Society of Nephrology (ISN) and the International Federation of Kidney Funds (IFKF), more than 500 million people in the world suffer from different types of kidney diseases; among them, patients with end-stage renal disease die of complications of cardiovascular and cerebrovascular diseases. The number of people reaches millions every year. Cardiovascular disease is a common complication of renal failure, and up to 50% of uremia patients die from this complication. In fact, uremia and cardiovascular and cerebrovascular diseases affect each ot...

AI Technical Summary

Problems solved by technology

At present, in the clinical treatment of in vitro low-density lipoprotein precipitation induced by heparin, since heparin is free, it is inevitable that some residues of heparin will enter the human body with the blood due to excessive use of heparin during the treatment cycle, which may cause bleeding, No blood coagulation and other side effects

In addition, for the combined treatment of hemodialysis and blood purification for uremia patients with cardiovascular and cerebrovascular diseases, there are still a series of practical problems such as cumbersome and lengthy treatment process, complicated operation, high price, and serious protein loss in patients.